BioLight announced today that it is expanding its Glaucoma and Dry Eye Syndrome Cluster by means of investing, through a wholly owned subsidiary, in D.E.S. Diagnostics Ltd., which is developing an innovative stick that enables diagnosis and monitoring of Dry Eye Syndrome by examining various parameters in tear fluid.
Bio-Light announced that positive interim results have been obtained from a clinical trial conducted to assess the capability of Zetiq’s (wholly owned subsidiary of Micromedic) CellDetect® technology, to detect bladder cancer cells in urine specimens.
Bio-Light announced that the product CellDetect®, manufactured by Zetiq – a subsidiary under the full control of Micromedic, designed to diagnose cancerous cells in the cervix, has been approved by the State Food and Drug Administration (SFDA) of the People’s Republic of China for marketing in China.
BioLight Life Sciences Investments Ltd., a unique Biomedical firm engaged in the management and commercialization of Biomed innovation, announced today that it has successfully raised over $28 million through shares issue at the market price to the company’s shareholders and other public investors. Among the investors are Mr. Israel Makov, …
BioLight Ltd. entered into an option agreement with Aerie Pharmaceuticals Inc., to license the Eye-DTM technology for further development of a sub-conjunctival drug implant for the controlled release of ophthalmic medications.
BioLight signed a non-binding Memorandum of Understanding between the company and an American company, engaged in the discovery and development of pharmaceuticals and medical devices and innovative treatment for glaucoma, for an Ocular implant for sustained release of drugs.
Under the MOU, the American company will give, through a subsidiary …